N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

N4 Pharma is a Derbyshire, England-based pharmaceutical company focused on the development of Nuvec.

Under the deal, N4 Pharma aims to combine Nuvec with SRI’s Fox Three Molecular Guidance System to

increase intracellular delivery to specific target cells.

On the back of the combined technology, the two companies will work collaboratively to develop and pursue new business opportunities, N4 Pharma said.

According to M4 Pharma, ‘SRI’s MGS technology is designed to overcome cellular barriers that prevent intracellular delivery of large molecule biotherapeutics.’ SRI is a California-based scientific research company.

Nuvec is a new delivery system for cancer treatments and vaccines.

N4 Pharma Chief Executive Officer Nigel Theobald said: ‘We are delighted to be working with SRI and to have entered into this collaboration agreement. Combining our technologies successfully will lead to working with major pharma companies in the fields of oncology and vaccines, with the exciting potential to develop novel products.

‘SRI collaborates with a broad range of partners from small and virtual biotechnology companies to top ten pharmaceutical companies and other leading industry partners, which will give us unparalleled access to potential commercial partners on the back of any successful combined technology resulting from our research.’

Shares in N4 Pharma were down 3.0% at 0.80 pence each in London on Thursday morning.

Copyright 2024 Alliance News Ltd. All Rights Reserved.